The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.
Sanofi and Regeneron Pharmaceuticals Inc. are moving swiftly to start trials to see whether their rheumatoid arthritis drug Kevzara could treat the symptoms of coronavirus.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
